Zyprexa At "Halftime": Lilly Remains Committed To Antipsychotic

Lilly's 2005 marketing strategy aims to stem declining sales for the atypical antipsychotic Zyprexa, Exec. VP-Pharmaceutical Operation John Lechleiter, PhD, said